Research & Development

Inspirna raises funds to advance clinical stage cancer drugs development

Inspirna has raised $50m in Series D financing round to advance the development of its clinical stage cancer drugs.

WuXi XDC, AbTis sign MoU to develop ADC products

WuXi XDC has signed a Memorandum of Understanding (MOU) with Korean biotechnology firm AbTis to develop and manufacture a portfolio of antibody-drug conjugates (ADC) products.

Exelixis, Ryvu Therapeutics to develop new targeted cancer therapies

Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies.

Turnstone, Moffitt Cancer Center partner to develop TIL cell therapies

Turnstone Biologics has formed a broad strategic alliance with Moffitt Cancer Center for advancing the development of next-generation tumour-infiltrating lymphocyte (TIL) therapies for solid tumours.

Mogrify, Astellas Pharma partner for sensorineural hearing loss treatment

UK-based Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Regeneron completes acquisition of Sanofi’s stake in Libtayo

Regeneron Pharmaceuticals has completed the purchase of Sanofi's stake in cancer drug Libtayo (cemiplimab).

Mesh Bio, MultiOmic partner to develop chronic metabolic disease medicines

Digital health start-up Mesh Bio has collaborated with drug discovery company MultiOmic Health to use artificial intelligence (AI) for developing precision medicines and diagnostics for chronic metabolic disease.

Generian, Astellas to develop molecules for undruggable therapeutic targets

Generian Pharmaceuticals has signed a collaboration and exclusive license agreement with Astellas Pharma’s wholly owned subsidiary Mitobridge for the research and development of new small molecules for undruggable therapeutic targets.

Palleon, Henlius partner for bifunctional sialidase therapies development

Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered into a strategic collaboration for the development and commercialisation of two bifunctional sialidase therapies.